Compare GSK plc (GSK) vs VICI Properties Inc (VICI) Price & Performance

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

VICI Properties trades at $26.03, down 0.17% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 67.5%, and a recent dividend of $0.45 paid in July 2026. Q2 2026 earnings saw an EPS miss at $0.48 versus $0.713 expected, though revenue beat forecasts, and the company raised its AFFO guidance.

Analyst consensus is strongly bullish with a $29.83 price target and 76.9% buy ratings, highlighting the 6.6% dividend yield and solid cash flow. Key risks include high debt levels, interest expense pressure, and uncertainty from the Caesars acquisition overhang, but the REIT's tangible assets and oligopoly advantages support long-term income appeal.